Corcept Therapeutics Incorporated

21.77+0.6600+3.13%Vol 693.19K1Y Perf -12.48%
Mar 24th, 2023 16:00 DELAYED
BID21.23 ASK22.32
Open21.13 Previous Close21.11
Pre-Market- After-Market21.77
 - -  - -%
Target Price
31.50 
Analyst Rating
Moderate Buy 2.17
Potential %
44.69 
Finscreener Ranking
★★★★+     57.46
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     61.29
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     81.58
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
35.37 
Earnings Rating
Strong Sell
Market Cap2.35B 
Earnings Date
4th May 2023
Alpha0.02 Standard Deviation0.14
Beta0.43 

Today's Price Range

21.0921.78

52W Range

17.1930.14

5 Year PE Ratio Range

10.80297.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
5.47%
1 Month
2.16%
3 Months
5.42%
6 Months
-13.20%
1 Year
-12.48%
3 Years
110.95%
5 Years
30.36%
10 Years
956.80%

TickerPriceChg.Chg.%
CORT21.770.66003.13
AAPL160.251.32000.83
GOOG106.08-0.1850-0.17
MSFT280.572.91001.05
XOM103.530.12000.12
WFC36.23-0.3800-1.04
JNJ152.651.52001.01
FB196.640.99000.51
GE91.37-0.2200-0.24
JPM124.91-1.9300-1.52
 
ProfitabilityValueIndustryS&P 500US Markets
98.70
31.90
32.60
36.50
28.39
RevenueValueIndustryS&P 500US Markets
298.80M
2.78
11.05
27.41
Earnings HistoryEstimateReportedSurprise %
Q04 20220.230.14-39.13
Q03 20220.230.3030.43
Q02 20220.250.24-4.00
Q01 20220.230.20-13.04
Q04 20210.220.2618.18
Q03 20210.190.2426.32
Q02 20210.140.2150.00
Q01 20210.210.18-14.29
Earnings Per EndEstimateRevision %Trend
12/2022 QR0.15-34.78Negative
12/2022 FY0.891.14Positive
3/2023 QR0.287.69Positive
12/2023 FY0.91-7.14Negative
Next Report Date4th May 2023
Estimated EPS Next Report0.23
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume693.19K
Shares Outstanding107.90K
Shares Float68.49M
Trades Count9.21K
Dollar Volume14.97M
Avg. Volume919.48K
Avg. Weekly Volume1.06M
Avg. Monthly Volume988.86K
Avg. Quarterly Volume711.78K

Corcept Therapeutics Incorporated (NASDAQ: CORT) stock closed at 21.77 per share at the end of the most recent trading day (a 3.13% change compared to the prior day closing price) with a volume of 693.19K shares and market capitalization of 2.35B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 236 people. Corcept Therapeutics Incorporated CEO is Joseph K. Belanoff.

The one-year performance of Corcept Therapeutics Incorporated stock is -12.48%, while year-to-date (YTD) performance is 7.19%. CORT stock has a five-year performance of 30.36%. Its 52-week range is between 17.19 and 30.14, which gives CORT stock a 52-week price range ratio of 35.37%

Corcept Therapeutics Incorporated currently has a PE ratio of 20.60, a price-to-book (PB) ratio of 4.69, a price-to-sale (PS) ratio of 7.39, a price to cashflow ratio of 17.80, a PEG ratio of 2.32, a ROA of 22.70%, a ROC of 22.65% and a ROE of 25.09%. The company’s profit margin is 28.39%, its EBITDA margin is 32.60%, and its revenue ttm is $298.80 Million , which makes it $2.78 revenue per share.

Of the last four earnings reports from Corcept Therapeutics Incorporated, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.23 for the next earnings report. Corcept Therapeutics Incorporated’s next earnings report date is 04th May 2023.

The consensus rating of Wall Street analysts for Corcept Therapeutics Incorporated is Moderate Buy (2.17), with a target price of $31.5, which is +44.69% compared to the current price. The earnings rating for Corcept Therapeutics Incorporated stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Corcept Therapeutics Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Corcept Therapeutics Incorporated has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.47, ATR14 : 0.69, CCI20 : 125.68, Chaikin Money Flow : -0.10, MACD : -0.19, Money Flow Index : 39.05, ROC : 3.62, RSI : 54.92, STOCH (14,3) : 99.25, STOCH RSI : 1.00, UO : 55.59, Williams %R : -0.75), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Corcept Therapeutics Incorporated in the last 12-months were: Daniel N. Swisher (Option Excercise at a value of $131 000), Daniel N. Swisher (Sold 15 385 shares of value $435 703 ), David L. Mahoney (Option Excercise at a value of $121 500), G. Charles Robb (Option Excercise at a value of $416 000), G. Charles Robb (Sold 158 401 shares of value $3 902 334 ), Hazel Hunt (Option Excercise at a value of $104 000), James N. Wilson (Option Excercise at a value of $624 000), Joseph K. Belanoff (Option Excercise at a value of $1 664 000), Joseph K. Belanoff (Sold 335 019 shares of value $8 798 951 ), Sean Maduck (Option Excercise at a value of $-309 604), Sean Maduck (Sold 100 825 shares of value $2 632 040 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (50.00 %)
3 (50.00 %)
4 (66.67 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (33.33 %)
2 (33.33 %)
1 (16.67 %)
Moderate Sell
1 (16.67 %)
1 (16.67 %)
1 (16.67 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.17
Moderate Buy
2.17
Moderate Buy
1.83

Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is engaged in the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

CEO: Joseph K. Belanoff

Telephone: +1 650 327-3270

Address: 149 Commonwealth Drive, Menlo Park 94025, CA, US

Number of employees: 236

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

59%41%


News

Stocktwits